Anti‐Osteoporosis and Bone Protective Effects of Resveratrol in Rats With Chronic Kidney Disease‐Induced Osteoporosis
Molecular Nutrition & Food Research · 2025
DOI: 10.1002/mnfr.70017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Nutrition & Food Research, 2025. Verfasst von Enzhe Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, Shanxi Bethune Hospital(Shanxi Academy of Medical Sciences), Third Hospital of Shanxi Medical University, Tongji Shanxi H…. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Osteoporosis, Bone Density Conservation Agents, Stilbenes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: Shanxi Provincial Basic Research Plan (Free Exploration).
Abstract (Originalsprache)
Chronic kidney disease (CKD)–induced osteoporosis is a new concept that implies CKD‐related impaired bone quality. Resveratrol (RES) is a natural component, known for its anti‐inflammatory and anti‐osteoporotic effects. In the present study, we aimed to investigate the bone‐protective and anti‐osteoporotic effects of resveratrol in rats with chronic kidney disease‐induced osteoporosis. The 5/6th nephrectomy (Nx) model of CKD was established. Resveratrol and alendronate (ALN), as standard drug, were administered for 45 days. Blood samples and femurs were collected and subjected to molecular analysis, micro‐CT, and bone mechanical tests. The results showed a significant decrease in Ca levels but no significant changes in 1,25 vitamin D and phosphorus levels in untreated and treated CKD groups. Treatment with RES and ALN did not reverse the increase of serum parathyroid hormone while reducing the elevated FGF‐23 levels. Unlike ALN, RES had no significant effect on increased alkaline phosphatas levels or decreased osteocalcin and OPG levels in CKD rats. Moreover, results showed that RES reversed the increase of RANKL and TRAP in serum and femur tissue close to the control level, leading to an improvement in bone strength and microarchitecture. In conclusion, the present study showed beneficial anti‐osteoporotic effects of RES on CKD‐induced osteoporosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, Shanxi Bethune Hospital(Shanxi Academy of Medical Sciences), Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, Shanxi, China.
- Department of Nephrology, Shanxi Provincial People's Hospital, Taiyuan, Shanxi, China.
ORCID-Profile: Rui Zhang
Förderung
- Shanxi Provincial Basic Research Plan (Free Exploration)
Zitieren
APA
Zhao, E., Zhu, J., Hao, H., Zhang, R., & Wu, D. (2025). Anti‐Osteoporosis and Bone Protective Effects of Resveratrol in Rats With Chronic Kidney Disease‐Induced Osteoporosis. Molecular Nutrition & Food Research. https://doi.org/10.1002/mnfr.70017
Vancouver
Zhao E, Zhu J, Hao H, Zhang R, Wu D. Anti‐Osteoporosis and Bone Protective Effects of Resveratrol in Rats With Chronic Kidney Disease‐Induced Osteoporosis. Molecular Nutrition & Food Research. 2025. doi:10.1002/mnfr.70017
BibTeX
@article{Zhao2025,
author = {Zhao, Enzhe and Zhu, Jian and Hao, Haihu and Zhang, Rui and Wu, Dou},
title = {Anti‐Osteoporosis and Bone Protective Effects of Resveratrol in Rats With Chronic Kidney Disease‐Induced Osteoporosis},
journal = {Molecular Nutrition & Food Research},
year = {2025},
doi = {10.1002/mnfr.70017}
}
EUVIMED